Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus for repeated implantation failure with elevated Th1/Th2 ratio
IRCT20231127060207N1Phase 2Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- May 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Recurrent Implantation Failure (RIF) comparing Tacrolimus with Placebo (2 arms). Primary endpoint: Clinical pregnancy onset. Started May 2024; status: completed.
02
Drugs
tacrolimus
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on IRCT20231127060207N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231127060207N1.